How to Reconstitute AOD9604 (Fragment 176-191)
A laboratory reconstitution guide for AOD9604 (Fragment 176-191), covering the compound's identifiers, the GH-IGF-1 axis context, and the handling considerations reported in the peptide research literature.
AOD9604, also written as AOD-9604 and known as hGH fragment 176-191 or Anti-Obesity Drug 9604, is a synthetic peptide fragment corresponding to the C-terminal region of human growth hormone. It is classified in the research literature among the peptides marketed as "research compounds" that are intended to modulate the growth hormone–insulin-like growth factor-1 (GH-IGF-1) axis, alongside GHRH analogues such as sermorelin and tesamorelin, growth hormone secretagogues such as GHRP-2, GHRP-6, hexarelin and ipamorelin, and IGF-1 analogues [1]. The evidence block supplied for this page does not provide a sequence, molecular formula, or molecular weight for AOD9604, so no such values are stated here; the identifiers available are its fragment designation (hGH 176-191) and its alternate name, Anti-Obesity Drug 9604 [2][3].
The work reviewed here centres on the GH-IGF-1 axis, the endocrine signalling system through which growth hormone release and downstream insulin-like growth factor-1 activity are coordinated, and which is the pathway family that AOD9604 is described as modulating in the peptide-therapy literature [1].
Research Studies
AOD9604 and its classification among GH-IGF-1 axis peptides
Reviews of performance-enhancing peptides describe AOD9604 (hGH 176-191) as one of the agents most commonly encountered in clinical practice and in online self-administration protocols, grouped with GHRH analogues and growth hormone secretagogues under the broader heading of peptides marketed as research compounds [1]. The same literature frames these agents as unregulated peptides whose intended action is modulation of the GH-IGF-1 axis, and notes that they circulate largely outside the approval pathways that govern licensed medicines [1]. This is a classification and regulatory observation rather than an efficacy finding; the evidence block does not report a controlled trial of AOD9604 in any population.
AOD9604 and the gray-market peptide landscape in sports medicine
A separate review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance lists AOD-9604 (Anti-Obesity Drug 9604) among the prominent unapproved peptides marketed directly to patients [2][3]. That review characterises peptides generally as short amino acid chains occupying a pharmacological niche between small-molecule drugs and large proteins, and describes a parallel gray market of unapproved compounds operating largely outside regulatory oversight, driven by patient demand for accelerated injury recovery and performance enhancement [2][3]. AOD9604 appears in that work as an example of the unapproved category, not as a compound for which musculoskeletal or performance outcomes were demonstrated.
AOD9604 and the boundaries of the available evidence
The evidence block does not contain animal-only or in vitro studies of AOD9604, and it does not contain human outcome data for the compound. What it contains is survey-level and regulatory-level description: AOD9604 is named as a GH-IGF-1 axis peptide encountered in self-administration protocols [1], and it is named as an unapproved peptide marketed direct to patients in sports medicine [2][3]. Any statement about its mechanism at the receptor level, its tissue distribution, or its effects in a model organism would go beyond what these sources support, and is therefore omitted from this page.
AOD9604 and analytical detection in blood matrices
Detection methodology is relevant to any laboratory working with peptide standards. A harmonised analytical workflow has been reported for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices, covering 54 prohibited substances, and the paper notes that earlier methods for small peptides in dried blood spots involved multiple sample-preparation steps that were labour-intensive and costly [4]. AOD9604 is not named in the portion of that work available here, so the workflow is cited as context for peptide detection generally rather than as an AOD9604-specific assay.
AOD9604 and the peptide therapeutics literature in orthopaedics
A review of therapeutic peptides in orthopaedics describes peptides as emerging adjuncts grounded in their ability to modulate molecular signalling networks, acting on pathways including PI3K/Akt, mTOR, MAPK, TGF-β and AMPK, and thereby influencing tissue regeneration [6]. That review is a general treatment of the peptide class; it does not report AOD9604-specific data in the material available here, and it is cited to indicate the pathway families against which peptide research is generally framed rather than to attribute any of those mechanisms to AOD9604.
AOD9604 and the regulatory status reported for unapproved peptides
The regulatory picture reported across the sources is consistent: AOD9604 is described as unapproved and as marketed outside standard oversight [2][3], and as an unregulated peptide sold under a research-compound label [1]. For a laboratory, this status has practical consequences for documentation, chain of custody, and the framing of any internal work, because the compound does not sit within an approved therapeutic category in the sources reviewed.
AOD9604 and comparison of evidence categories across the cited sources
The table below summarises what each cited source contributes with respect to AOD9604, so that the strength and type of each statement can be seen at a glance.
| Source | Evidence type | What it states about AOD9604 |
|---|---|---|
| [1] | Review of clinical and self-administration landscape | Names AOD9604 (hGH 176-191) among GH-IGF-1 axis peptides marketed as research compounds and encountered in self-administration protocols |
| [2][3] | Review of approved and unapproved peptide therapies | Lists AOD-9604 (Anti-Obesity Drug 9604) among unapproved peptides marketed direct to patients in sports medicine |
| [4] | Analytical methods paper | Reports a harmonised detection workflow for 54 prohibited substances in blood matrices; AOD9604 not named in the available portion |
| [6] | Review of peptide therapeutics in orthopaedics | Describes peptide modulation of PI3K/Akt, mTOR, MAPK, TGF-β and AMPK pathways; no AOD9604-specific data in the available portion |
AOD9604 and the handling implications of a research-only designation
Because the sources describe AOD9604 as an unapproved, unregulated peptide sold as a research compound [1][2][3], the handling context for laboratory work is defined by internal research protocols rather than by a therapeutic label. The evidence block does not supply stability data, storage temperatures, solvent compatibility, or reconstitution volumes for AOD9604, and none are invented here. What the sources do support is the general point that peptides are short amino acid chains with a pharmacological profile distinct from small molecules and large proteins [2][3], which is the reason peptide handling and detection are treated as their own methodological problem in the analytical literature [4].
AOD9604 and the absence of population-level outcome data in the cited evidence
No population is named in the evidence block for whom an AOD9604 effect was observed. The cited reviews discuss AOD9604 as a named agent within broader categories — GH-IGF-1 axis peptides [1] and unapproved peptides marketed to patients [2][3] — and do not report an outcome measured in animals, in vitro preparations, or humans. This page therefore states no effect, in no population, and confines itself to the classification, regulatory and detection context that the sources actually provide.
If you are reading this for personal health reasons
This material is sold for laboratory research only, and we do not provide dosing or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician. Nothing on this page is a recommendation for personal use.
Sources
- [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — https://europepmc.org/article/PMC/PMC13322892
- [2] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v3
- [3] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v1
- [4] Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices — https://pubmed.ncbi.nlm.nih.gov/42328738/
- [5] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://pubmed.ncbi.nlm.nih.gov/41966639/
- [6] Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — https://europepmc.org/article/PMC/PMC12753158